Nathanael R. Fillmore
Publications / 2026
paper
JAMA2026doi:10.1001/jama.2026.13471

Active Surveillance Use for Favorable-Risk Prostate Cancer in a Veterans Affairs Population.

Grace Lee†, John R. Bihn†, John M. Culnan, Jennifer La, Nhan V. Do, Kenute Myrie, Channing J. Paller, Nathanael R. Fillmore‡, Matthew R. Cooperberg‡, PROFOUND-VET Investigators

† Equal first authorship · ‡ Equal senior authorship

Summary

Active surveillance rates for low-risk prostate cancer in the Veterans Affairs Healthcare System increased from 27% to 93% between 2005 and 2024. This trend indicates a strong alignment with clinical guidelines to reduce unnecessary treatments, although disparities in surveillance use persist among Black and Hispanic patients.

Key result

Active surveillance use among patients with low-risk prostate cancer increased from 27% to 93%, and from 14% to 61% among those with favorable intermediate-risk disease, between 2005 and 2024.

Key figure

Key figure from Active Surveillance Use for Favorable-Risk Prostate Cancer in a Veterans Affairs Population.